Department of Womens's Health, University of Southern Denmark, Sygehus Sønderjylland, Aabenraa, Denmark.
Department of Clinical Research, University of Southern Denmark, Sygehus Sønderjylland, Aabenraa, Denmark.
PLoS One. 2024 Jun 14;19(6):e0303989. doi: 10.1371/journal.pone.0303989. eCollection 2024.
Identifying and describing molecular alterations in tumors has become common with the development of high-throughput sequencing. However, DNA sequencing in rare tumors, such as ovarian adult granulosa cell tumor (aGCT), often lacks statistical power due to the limited number of cases in each study. Questions regarding personalized treatment or prognostic biomarkers for recurrence or other malignancies therefore still need to be elucidated. This scoping review protocol aims to systematically map the current evidence and identify knowledge gaps regarding DNA alterations, actionable variations and prognostic biomarkers in aGCT.
This scoping review will be conducted based on Arksey and O'Malley's methodological framework and later modifications by JBI Evidence Synthesis. The protocol complies with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. All original publications describing molecular alterations of aGCT will be included. The search will be performed in May 2024 in the following databases: MEDLINE (Ovid), Embase (Ovid), Web of Science Core Collection and Google Scholar (100-top ranked).
This scoping review will identify knowledge and gaps in the current understanding of the molecular landscape of aGCT, clinical trials on actionable variations and priorities for future research. As aGCT are rare, a possible limitation will be the small sample sizes and heterogenic study settings.
The review protocol is registered at Open Science Framework under https://doi.org/10.17605/OSF.IO/PX4MF.
随着高通量测序技术的发展，鉴定和描述肿瘤中的分子改变已变得普遍。然而，由于每个研究中的病例数量有限，在罕见肿瘤（如卵巢成人颗粒细胞瘤[aGCT]）中进行 DNA 测序往往缺乏统计学效力。因此，关于复发或其他恶性肿瘤的个性化治疗或预后生物标志物的问题仍需阐明。本范围综述方案旨在系统地绘制目前关于 aGCT 中 DNA 改变、可操作变异和预后生物标志物的证据，并确定知识空白。
本范围综述将根据 Arksey 和 O'Malley 的方法学框架进行，并根据 JBI 证据综合的后续修改进行。该方案符合系统评价和荟萃分析扩展的首选报告项目，用于范围综述。所有描述 aGCT 分子改变的原始出版物都将被包括在内。搜索将于 2024 年 5 月在以下数据库中进行：MEDLINE（Ovid）、Embase（Ovid）、Web of Science 核心合集和 Google Scholar（排名前 100）。
本范围综述将确定当前对 aGCT 分子景观、可操作变异的临床试验以及未来研究重点的理解中的知识和空白。由于 aGCT 较为罕见，因此可能的限制因素是样本量小和研究设置异质性。
该综述方案在 Open Science Framework 上注册，网址为 https://doi.org/10.17605/OSF.IO/PX4MF。
